BioCentury | Jun 26, 2020
Distillery Therapeutics

MAP3K7, IL18R1 as targets in obesity-related cerebrovascular dysfunction

DISEASE CATEGORY: Endocrine/metabolic; neurology INDICATION: Obesity; stroke Inhibiting MAP3K7 or the IL-18 receptor subunit IL18R1 could treat obesity-associated cerebrovascular dysfunction. In cultured rat aortic endothelial cells, an siRNA against IL18R1 increased levels of phosphorylated NOS3,...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

Boehringer is showing itself to be a stealthy but serious player in cutting-edge science with the latest in a series of early-stage deals that come with little notice and plant a flag in an important...
BioCentury | May 1, 2020
Distillery Therapeutics

Disrupting hypoxia signaling to treat a muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy The PI3K-mTOR pathway inhibitors could treat facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle wasting disorder caused by inappropriate DUX4 expression, by disrupting the hypoxia signaling pathway. In a DUX4-expressing...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Hyaluronic acid, collagen to prevent intervertebral disc degeneration after herniation

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal An injectable therapy comprising hyaluronic acid and a high-density collagen patch could prevent acute intervertebral disc degeneration after herniation as well as subsequent discectomy. The strategy involves injecting a hexadecyl...
BioCentury | Jan 31, 2020
Distillery Therapeutics

FERMT2 identified as target in renal fibrosis

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the focal adhesion molecule FERMT2 could treat renal fibrosis. In renal tissue from patients with renal fibrosis, FERMT2 levels were higher in fibrotic tissue than in normal tissue....
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BC Extra | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
Items per page:
1 - 10 of 1121